INTERLEUKIN GENETICS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-27: Form 8-K; Period of report 2013-11-25; Description 8.01 Other Events; Details 8.01.
- 2013-11-07: Form 8-K; Period of report 2013-11-01; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2013-08-15: Form 8-K; Period of report 2013-08-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-08-13: Form 8-K; Period of report 2013-08-09; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-27 | 8-K | 2013-11-25 | 8.01 Other Events | 8.01 On November 25, 2013, Interleukin Genetics, Inc. (the “Company”) issued a press release announcing the introduction of PerioPredict™, the Company’s new, next-generation version of the PST® genetic risk test for periodontal disease. | v361744_8k.htm |
| 2013-11-07 | 8-K | 2013-11-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | v359699_8k.htm |
| 2013-08-15 | 8-K | 2013-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2013, Interleukin Genetics, Inc. (the “Company”) issued a press release in which it reported its financial results for the quarter ended June 30, 2013. | v353100_8k.htm |
| 2013-08-13 | 8-K | 2013-08-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 (e) On August 9, 2013, at the 2013 Annual Meeting of Stockholders (the “Annual Meeting”) of Interleukin Genetics, Inc. (the “Company”), the shareholders approved the Company’s 2013 Employee, Director and Consultant Equity Incentive Plan (the “Stock Plan”), as described under Proposal 4 of Item 5.07 below. 5.03 On August 9, 2013, the Company filed a certificate of amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 300,000,000. 5.07 At the Annual Meeting, at which a quorum was present, the stockholders of the Company voted on and approved the following matters, which are described in detail in the Proxy Statement: (1) to elect William C. Mills III and James M. Weaver as Class I directors to each serve for a three-year term expiring at the Company’s 2016 annual meeting of stockholders (“Proposal 1”); (2) to approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 300,000,000 (“Proposal 2”); (3) to approve an amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split by combining outstanding shares of the Company’s common stock into a lesser number of outstanding shares by a ratio of not less than 1-for-5 and not more than 1-for-20 at any time prior to the earlier of (i) August 1, 2014 and (ii) the 2014 annual meeting of stockholders, with the exact ratio to be set within this range by the Company’s board of directors in its sole discretion (“Proposal 3”); (4) to approve the 2013 Employee, Director and Consultant Equity Incentive Plan (“Proposal 4”); (5) to ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013 (“Proposal 5”); (6) to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (“Proposal 6”); and (7) to approve, on an advisory basis, the frequency of having an advisory vote on the compensation of the Company’s named executive officers (“Proposal 7”). | v352713_8k.htm |
| 2013-06-05 | 8-K | 2013-05-31 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 (a) On May 17, 2013, Interleukin Genetics, Inc. (the “Company” or “Interleukin”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with various accredited investors (the “Purchasers”), pursuant to which Interleukin sold securities to the Purchasers in a private placement transaction (the “Offering”). | v346995_8k.htm |
| 2013-06-05 | 8-K/A | 2013-05-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) Prior to the Offering, the Board of Directors of the Company consisted of six directors. | v346985_8ka.htm |
| 2013-05-20 | 8-K | 2013-05-17 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 On May 17, 2013, Interleukin Genetics, Inc. (the “Company” or “Interleukin”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with various accredited investors (the “Purchasers”), pursuant to which Interleukin sold securities to the Purchasers in a private placement transaction (the “Offering”). 3.02 The disclosure set forth above in Item 1.01 is hereby incorporated by reference into this Item 3.02. 5.02 (b) Prior to the Offering, the Board of Directors of the Company consisted of six directors. 8.01 On May 20, 2013, the Company issued a press release announcing the Offering. | v345650_8k.htm |
| 2013-03-28 | 8-K | 2013-03-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 27, 2013, Thomas R. Curran, Jr. announced that he was resigning as a director of Interleukin Genetics, Inc. (the “Company”) and as a member of all committees of the Company’s Board of Directors on which he serves, effective as of the close of business on March 28, 2013. | v339734_8k.htm |
| 2013-03-01 | 8-K | 2013-02-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 25, 2013, Interleukin Genetics, Inc. (the “Company”) entered into a Preferred Participation Agreement (the “Agreement”) with Renaissance Health Service Corporation, for itself and on behalf of certain of its affiliates and subsidiaries. | v336772_8k.htm |
| 2013-01-03 | 8-K | 2013-01-03 | 8.01 Other Events | 8.01 On January 3, 2013, Interleukin Genetics, Inc. issued a press release announcing the appointment of Scott Snyder as Chief Marketing Officer. | v331380_8k.htm |